Company WuXi Biologics (Cayman) Inc. OTC Markets
Stocks
WXXW.Y
US98260N1081
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.540 USD | -0.79% |
|
-8.16% | -5.75% |
| Jun. 05 | Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub | CI |
| May. 31 | Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth | RE |
Business description: WuXi Biologics (Cayman) Inc.
Number of employees: 13,252
Sales by Activity: WuXi Biologics (Cayman) Inc.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Biologics | - | - | 16.03B | 16.51B | 18.14B |
Biotechnology | 10.29B | 15.27B | - | - | - |
Xdc | - | - | 2.12B | 4.05B | 5.94B |
Adjustments and Eliminations | - | - | -1.12B | -1.89B | -2.29B |
Geographical breakdown of sales: WuXi Biologics (Cayman) Inc.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
North America | 5.23B | 8.5B | 8.07B | 10.7B | 12.65B |
Europe | 2.28B | 2.55B | 5.14B | 4.32B | 5.04B |
People's Republic of China (PRC) | 2.51B | 3.72B | 3.12B | 2.82B | 2.68B |
Rest of The World | 274M | 507M | 698M | 836M | 1.41B |
Executive Committee: WuXi Biologics (Cayman) Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 54 | 2015-12-31 |
Ming Tu
DFI | Director of Finance/CFO | 56 | 2021-08-22 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 55 | 2024-03-30 |
He Wang
CMP | Compliance Officer | - | - |
Lihua Yu
COO | Chief Operating Officer | - | - |
Composition of the Board of Directors: WuXi Biologics (Cayman) Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Ge Li
CHM | Chairman | 59 | 2014-01-31 |
Zhi Sheng Chen
BRD | Director/Board Member | 54 | 2014-01-31 |
Yan Ling Cao
BRD | Director/Board Member | 42 | 2016-04-30 |
William Keller
BRD | Director/Board Member | 77 | 2017-05-16 |
Kenneth Hitchner
BRD | Director/Board Member | 65 | 2020-06-08 |
Jackson Tai
BRD | Director/Board Member | 75 | 2023-05-05 |
Jue Chen
BRD | Director/Board Member | 56 | 2023-08-15 |
Xuejun Gu
BRD | Director/Board Member | 55 | 2025-06-05 |
Jingwen Miao
BRD | Director/Board Member | - | 2024-11-19 |
Holdings: WuXi Biologics (Cayman) Inc.
| Name | Stocks | % | Valuation |
|---|---|---|---|
WUXI XDC CAYMAN INC. 50.41% | 635,484,500 | 50.41% | 4 451 M $ |
| 96,859,693 | 16.27% | 25 M $ |
Company details: WuXi Biologics (Cayman) Inc.
Group companies: WuXi Biologics (Cayman) Inc.
| Name | Category and Sector |
|---|---|
WuXi Biologics (Hong Kong) Ltd. |
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.66% | +9.72% | +50.20% | +106.22% | 54.5B | |
| +3.81% | -2.72% | +49.75% | +43.89% | 41.73B | |
| -0.36% | -2.20% | -19.08% | -21.21% | 21.87B | |
| -6.46% | -10.74% | +1.95% | +375.41% | 21.47B | |
| -0.16% | +5.51% | +7.56% | -40.44% | 15.29B | |
| -0.36% | +2.91% | +24.88% | +178.16% | 13.32B | |
| +3.61% | -0.55% | +16.69% | - | 11.53B | |
| -11.72% | -15.43% | -42.28% | +616.01% | 11.09B | |
| -0.40% | +9.31% | +100.40% | +225.17% | 11.63B | |
| Average | -1.25% | +1.42% | +21.12% | +185.40% | 22.49B | |
| Weighted average by Cap. | -0.25% | +2.53% | +28.53% | +138.40% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2269 Stock
- WXXW.Y Stock
- Company WuXi Biologics (Cayman) Inc.
Select your edition
All financial news and data tailored to specific country editions
